Key Points Interested in Nano Nuclear Energy Inc.? Here are five stocks we like better. Nano Nuclear Energy's shares rose 11% ...

A new price target on Nano Nuclear Energy has generated excitement. Should you buy this microreactor developer?

For more than 40 years, the Kronos Quartet—David Harrington (violin), John Sherba (violin), Hank Dutt (viola), and Sunny Yang (cello)—has pursued a singular artistic vision, combining a spirit of ...

As many as 950 employees of Ultimate Kronos Group (UKG), many of them from offices in Sunrise and Weston, were notified on Wednesday that their jobs would be eliminated in an apparent global ...

We rarely invite the same band back to the Tiny Desk. But the beloved Kronos Quartet, which first played our offices 12 years ago, isn't the same band. Three of the four members are brand new: Cellist ...

Ignota Labs has harvested more assets for its drug candidate rehabilitation scheme, snapping up Kronos Bio’s clinical pipeline months after a series of setbacks drove the biotech off public markets. U ...

The new Kronos IEMs from have nine drivers and a six-way crossover but an impedance of less than 35Ω. Noble Audio has announced the launch of its latest pair of flagship in-ear monitors. The Kronos ...

Today (July 16) marks the 80th anniversary of the Trinity test, during which a team of U.S. scientists led by J. Robert Oppenheimer detonated the world’s first atomic bomb in the deserts of New Mexico ...

Get exclusive reporting, live Q&As and ad-free reading. It’s a question Asa Chandler hasn’t stopped asking since he heard his old friend Tony Kronos was missing. The 40-year-old was last seen at his ...

Concentra Biosciences inked a definitive deal to acquire Kronos Bio’s common stock for 57 cents per share. (cagkansayin/GettyImages) With the walls quickly closing ...

Google has unveiled a new quantum computer and is once more claiming to have pulled ahead in the race to show that these exotic machines can beat even the world’s best conventional supercomputers – so ...

Kronos Bio, a San Mateo biotech company, is losing millions of dollars a month and recently had to discontinue its sole clinical-stage compound because of adverse side effects. Now, the company is ...